Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sage Therapeutic Com (SAGE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 2,349,315
  • Shares Outstanding, K 37,350
  • Annual Sales, $ 0 K
  • Annual Income, $ -158,990 K
  • 36-Month Beta 2.94
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 9.32

Price Performance

See More
Period Period Low Period High Performance
1-Month
60.23 +4.43%
on 09/18/17
90.80 -30.73%
on 09/08/17
-19.16 (-23.35%)
since 08/22/17
3-Month
60.23 +4.43%
on 09/18/17
90.80 -30.73%
on 09/08/17
-22.04 (-25.95%)
since 06/22/17
52-Week
38.30 +64.23%
on 11/03/16
90.80 -30.73%
on 09/08/17
+17.08 (+37.28%)
since 09/22/16

Most Recent Stories

More News
Sage Therapeutics to Participate in Leerink Investor Conference

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that...

SAGE : 62.90 (-3.22%)
Implied Volatility Surging for Sage Therapeutics, Inc. (SAGE) Stock Options

Surging implied volatility makes Sage Therapeutics, Inc. (SAGE) stock lucrative to the option traders.

SAGE : 62.90 (-3.22%)
Corporate News Blog - Sage Therapeutics Announces Top-Line Results from Phase-3 STATUS Trial of Brexanolone

Research Desk Line-up: Cellect Biotech Post Earnings Coverage

SAGE : 62.90 (-3.22%)
APOP : 8.28 (+2.35%)
Biotech Stock Roundup: Alexion to Cut Jobs, Streamline Operations, Kura Up on Cancer Data

Key highlights include Alexion's (ALXN) restructuring plans and promising data from Kura Oncology on its lead pipeline candidate.

VRTX : 151.26 (-0.53%)
KURA : 12.00 (-3.23%)
SAGE : 62.90 (-3.22%)
ABBV : 87.48 (+0.08%)
REGN : 432.72 (-0.17%)
ICPT : 61.59 (-16.43%)
ALXN : 142.82 (-0.07%)
DowDuPont and US Bancorp climb while Cooper Cos. slides

NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday:

SAGE : 62.90 (-3.22%)
ALXN : 142.82 (-0.07%)
Sage Therapeutics Reports Top-Line Results from Phase 3 STATUS Trial of Brexanolone in Super-Refractory Status Epilepticus

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today reported top-line...

SAGE : 62.90 (-3.22%)
Sage Therapeutics to Present at Morgan Stanley Healthcare Conference

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that...

MS : 48.22 (-0.08%)
SAGE : 62.90 (-3.22%)
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, announced that, on September...

SAGE : 62.90 (-3.22%)
Options Traders Expect Huge Moves in Sage Therapeutics (SAGE) Stock

Options Traders Expect Huge Moves in Sage Therapeutics (SAGE) Stock on the back of its high level of implied volatility.

SAGE : 62.90 (-3.22%)
Sage Therapeutic Has Returned 23.1% Since SmarTrend Recommendation (SAGE)

SmarTrend identified an Uptrend for Sage Therapeutic (NASDAQ:SAGE) on June 7th, 2017 at $71.91. In approximately 2 months, Sage Therapeutic has returned 23.08% as of today's recent price of $88.51.

SAGE : 62.90 (-3.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators mostly agree with the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

SAGE Therapeutics Inc. is a biopharmaceutical company developing and commercializing medicines to treat life-threatening central nervous system (CNS) disorders. The Company provides treatments for schizophrenia, major depressive disorder, pain, and traumatic brain injury conditions. Its initial product...

See More

Support & Resistance

2nd Resistance Point 66.47
1st Resistance Point 64.69
Last Price 62.90
1st Support Level 61.91
2nd Support Level 60.91

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.